ライフサイエンスコーパス: long-term follow-up

1 atients with Behcet disease, especially with long term follow up.

2 prediction of arrhythmia recurrences during long term follow-up.

3 sentation, had moderate to severe VA loss at long term follow-up.

4 egistry, ISRCTN10356387, and is currently in long-term follow up.

5 ciety Knee Function Scores were found during long-term follow up.

6 ecurrences after AF catheter ablation during long-term follow-up.

7 dence base to inform priorities for clinical long-term follow-up.

8 neity, reporting of side effects and lack of long-term follow-up.

9 ated with any increase in ischemic events at long-term follow-up.

10 alization and less inpatient spending during long-term follow-up.

11 ry, and quality of life in both hospital and long-term follow-up.

12 ongestive heart failure were assessed during long-term follow-up.

13 ious adverse events were not analysed in the long-term follow-up.

14 ed; no new safety data were collected during long-term follow-up.

15 d the probability of re-bleeding episodes in long-term follow-up.

16 -term outcomes have longer graft survival on long-term follow-up.

17 is in functional limb weakness is rare after long-term follow-up.

18 Over 70% of survivors had proteinuria on long-term follow-up.

19 s, virtually all consented to registry-based long-term follow-up.

20 tion, stroke, or repeat revascularization at long-term follow-up.

21 cal prognostic factors related to IBTR using long-term follow-up.

22 s in a large, randomized clinical trial with long-term follow-up.

23 Patient outcomes have not been assessed in long-term follow-up.

24 epithelial off cross-linking (CXL) during a long-term follow-up.

25 been used with poor disease-free survival at long-term follow-up.

26 5-11.54; p<0.0001), and was sustained during long-term follow-up.

27 coronary artery dissection are common during long-term follow-up.

28 outcome measures, and results at short- and long-term follow-up.

29 e death, myocardial infarction, or stroke at long-term follow-up.

30 or myocardial infarction both at short- and long-term follow-up.

31 f HCM patients with LV apical aneurysms over long-term follow-up.

32 indfulness were not significant at short- or long-term follow-up.

33 initial assessment and in 10%-15% even after long-term follow-up.

34 ssociated with stable visual outcomes during long-term follow-up.

35 ation to aggressive lymphoma (4%), requiring long-term follow-up.

36 n, closed), and time between steps through a long-term follow-up.

37 treatment but 54 patients were continuing in long-term follow-up.

38 ains lower than that in patients with NFM at long-term follow-up.

39 ave a high probability of progressing during long-term follow-up.

40 rial tachycardia off antiarrhythmic drugs at long-term follow-up.

41 a woman's preferences, with a commitment to long-term follow-up.

42 receiving noninvasive ventilation including long-term follow-up.

43 ction, and reduced left atrial function over long-term follow-up.

44 e antigen (HBsAg), with 20% HBsAg loss after long-term follow-up.

45 with IVF reveal a specific diagnosis during long-term follow-up.

46 nterventions (21.6% vs 3.6%; P = .03) during long-term follow-up.

47 ss, and thus facilitate a personalization of long-term follow-up.

48 to hand or forearm symptoms, even at a very-long-term follow-up.

49 ion, immediate post CAR-T-cell infusion, and long-term follow-up.

50 ith similar risk of target-vessel failure at long-term follow-up.

51 e in the SSIS area is acceptable, even after long-term follow-up.

52 nts included HF alone and death alone during long-term follow-up.

53 treated with the Stanford V regimen and had long-term follow-up.

54 atment surveillance, to ongoing therapy, and long-term follow-up.

55 weight regain is a relevant issue in mid- to long-term follow-up.

56 ot derive clinical benefit with CRT-D during long-term follow-up.

57 h types of TTS showed a similar prognosis at long-term follow-up.

58 he difference in maximum walking distance at long-term follow-up.

59 ot different between the 2 treatments during long-term follow-up.

60 ession in a low-risk study population during long-term follow-up.

61 reased risk for VTE, which persisted through long-term follow-up.

62 , hospital discharge, 3-month follow-up, and long-term follow-up.

63 nt clinical symptoms at diagnosis and during long-term follow-up.

64 cy, (5) delivery, (6) graft removal, and (7) long-term follow-up.

65 l index and quality of life was found during long-term follow-up.

66 romising results, however there is a lack of long-term follow-up.

67 ys after randomization and maintained during long-term follow-up.

68 f GBA1 variants in incident PD patients with long-term follow-up.

69 wer all-cause mortality than with PCI-DES in long-term follow-up.

70 ve not been described in large datasets with long-term follow-up.

71 Three patients (5%) developed cysts at long-term follow-up, 1 of whom developed radionecrosis r

72 A minority of patients developed cysts at long-term follow-up, 1 of whom had permanent neurologica

73 with a new prospective cohort and report the long-term follow-up (10-years) using an intention-to-tre

74 From index admission to long-term follow-up, 19 patients (44%) died or had major

75 At long-term follow-up, 24.7% (95% confidence interval (CI)

76 Of 6 infants with long-term follow-up, 3 (50%) have demonstrated ZIKV-rela

77 During long-term follow-up, 412 patients had >=1 HHF and 333 ha

78 ECT treatment "index" (~4 weeks), and after long-term follow-up (6 months).

79 Between day 30 and long-term follow-up, 65 deaths occurred in the thromboly

80 flight (n = 11), postflight (n = 11), and at long-term follow-up 7 mo after landing (n = 7).

81 all studies comparing ASA with myectomy with long-term follow-up, (aborted) sudden cardiac death and

82 oup analysis was undertaken on patients with long-term follow-up, according to whether they were moni

83 Long-term follow up after combination therapy versus sup

84 Long-term follow-up after a clinical trial of 2 often-us

85 ents than the control population, warranting long-term follow-up after congenital cardiac surgery.

86 erosis by Noninvasive Imaging Research) with long-term follow-up after coronary artery calcium measur

87 We emphasize the need for regular and long-term follow-up after pediatric cataract surgery.

88 there is a scarcity of data regarding their long-term follow-up after surgical resection.

89 ontrolled trial, and observational posttrial long-term follow-up, after excluding individuals with ev

90 The primary endpoint of this long-term follow-up analysis was progression-free surviv

91 This Article reports on long-term follow-up analysis.

92 optimal vision and cost-effectiveness, as is long-term follow-up and adherence to treatment.

93 om 9 global clinical trials (2009-2017) with long-term follow-up and blinded, centrally adjudicated c

94 rom patients' bone marrow plasma cells, with long-term follow-up and clinicopathological data.

95 Larger leadless pacing trials, with long-term follow-up and direct randomized comparison wit

96 ngitudinal glaucoma progression studies with long-term follow-up and discuss the clinical relevance o

97 e single institution, which enables vigorous long-term follow-up and implant tracking for more accura

98 Long-term follow-up and management of donors was underta

99 n apparently "cured" patients could optimize long-term follow-up and modify decision-making regarding

100 e associated with cardiovascular outcomes in long-term follow-up and provide incremental value over t

101 rior to AMIO in achieving freedom from AF at long-term follow-up and reducing unplanned hospitalizati

102 hermore, data from longitudinal studies with long-term follow-up and repeated anthropometric measures

103 e-like anchor protein (LRBA) deficiency, but long-term follow-up and survival data beyond previous pa

104 increased and EATd consistently decreased at long-term follow-up and these changes were independent o

105 ith stereotactic radiosurgery remains low at long-term follow-up, and is similar to the risk of the g

106 ted with delayed HBeAg seroconversion during long-term follow-up, and more HBV genotype C infection a

107 acy of new-generation drug-eluting stents at long-term follow-up, and specifically in patients with S

108 Our results emphasize the importance of long-term follow-up, and the need for more efficacious a

109 In 9 cardiometabolic clinical trials with long-term follow-up, approximately 16% of deaths had und

110 prospective human intervention studies with long-term follow-up are available.

111 reverse causation, prospective studies with long-term follow-up are needed to evaluate associations

112 educate patients on the importance of close, long-term follow-up as a result of the uncertain nature

113 (TAVR) are sparse and limited by the lack of long-term follow-up as well as a direct comparison with

114 A long-term follow-up assessment was undertaken for patien

115 At long-term follow-up at 46.1 months, total survival was 5

116 B or C, and without liver cirrhosis, who had long-term follow-up at the National Taiwan University Ho

117 ch therapy worldwide and the limited data on long-term follow-up because the therapy has only been av

118 Long-term follow-up by way of a contrast-enhanced CT rev

119 This study highlights the need for targeted long-term follow-up care, physical rehabilitation, menta

120 We conducted a prospective long-term follow-up cohort study included 263 KTRs with

121 ECG and clinical parameters, sinus rhythm at long-term follow-up could be predicted with a mean AUC o

122 The long-term follow up data of 2 prospective phase II trial

123 with HER2-positive early breast cancer, but long-term follow-up data are needed.

124 Long-term follow-up data are still needed; in the end, p

125 Long-term follow-up data for disease recurrence and surv

126 Here, we report long-term follow-up data from study CA209-004, including

127 a significant limitation, as is the lack of long-term follow-up data in the majority of identified C

128 Conclusion Long-term follow-up data of the four randomized trials l

129 Nevertheless, long-term follow-up data of the leading bioresorbable sc

130 n's vaccination status was unknown, and that long-term follow-up data on disease detection in screen-

131 Long-term follow-up data on recurrence after surgical re

132 There are long-term follow-up data on the efficacy of ranibizumab

133 s issue of Blood, Lin et al report the first long-term follow-up data showing that Bruton tyrosine ki

134 Long-term follow-up data suggest both efficacy and safet

135 Long-term follow-up data were also collected for all pat

136 ssessment by the treating ED physician or by long-term follow-up data.

137 This publication provides long-term follow-up data.

138 re monitored without treatment had available long-term follow-up data.

139 The authors used an open-label, long-term follow-up design to examine participants enrol

140 progression of microvascular outcomes in the long-term follow-up Epidemiology of Diabetes Interventio

141 ave been focused on technical analyses and a long-term follow-up, especially on thrombotic total occl

142 rate, complications and clinical results in long term follow up for computed tomography (CT)-guided

143 s of active PDR in any or both eyes, who had long term follow-up for up to 10 years were included.

144 ecognised as chronic conditions that require long-term follow-up for adverse health sequelae in adult

145 n inform guideline-based recommendations for long-term follow-up for cataract.

146 nal cohort with 173 at-risk patients who had long-term follow-up for HCC development.

147 and 120 days) and ipsilateral stroke during long-term follow-up for patients assigned to CAS or CEA.

148 Here, we report the long-term follow-up for the addition of beta2-adrenergic

149 hese subjects were more likely to die during long-term follow up (for severe PHT, adjusted hazard rat

150 This registry-based analysis with long-term follow-up found no differences in graft and re

151 cation were predictive of tooth loss after a long-term follow-up (>10 years) in patients with periodo

152 ance recommendations vary among the existing long-term follow-up guidelines, which impedes the implem

153 s adopted from the Children's Oncology Group Long-Term Follow-Up Guidelines.

154 Using data from detailed Gulf Long-term Follow-up ( GuLF) Study enrollment interviews,

155 Long-term follow-up has now been completed, with the fin

156 Initial results of long-term follow-up have found a survival benefit in thi

157 (n = 780) increased the risk of diabetes at long-term follow-up (HR, 1.4; 95% CI, 1.0 to 2.0) but no

158 secondary aim was to review the outcomes and long term follow up in comparison to available studies o

159 At long-term follow-up in 28 patients at a median of 17.2 (

160 through a systems immunology approach, after long-term follow-up in a subsample (n = 171).

161 Long-term follow-up in children with NF1-associated OPGs

162 We describe baseline characteristics and long-term follow-up in patients who experienced CR with

163 sion capable of predicting abstinence during long-term follow-up in patients with AH.

164 BG + OMT reduced the primary endpoint during long-term follow-up in patients with type 2 diabetes and

165 ce in target vessel failure at 12 months and long-term follow-up in the stent-only versus the balloon

166 ive headache scores at median (12-month) and long-term follow-up, in addition to individual imaging d

167 A long-term follow-up including Quality of Life and pain s

168 The long-term follow-up indicated that, in selected cases of

169 Long-term follow-up is especially important for those wi

170 Therefore, long-term follow-up is generally recommended.

171 Long-term follow-up is important to judge both efficacy

172 rial data show encouraging results; however, long-term follow-up is lacking, and the safety and effic

173 Long-term follow-up is necessary for these patients, and

174 Long-term follow-up is necessary to understand the natur

175 Long-term follow-up is needed to determine the visual si

176 eferral for patients on dialysis in Georgia; long-term follow-up is needed to determine whether these

177 Long-term follow-up is needed to establish durable oncol

178 Metastases have been observed, and long-term follow-up is needed.

179 Long-term follow-up is often missing in the complex sett

180 Data collection for long-term follow-up is ongoing, but the trial is closed

181 Recruitment to all cohorts is complete and long-term follow-up is ongoing.

182 Recruitment is complete and long-term follow-up is ongoing.

183 TN67901257, and is no longer recruiting, but long-term follow-up is ongoing.

184 Assessment of new conditions at long-term follow-up is planned as this registry grows an

185 n of risk factors and patient selection in a long-term follow-up is warranted.

186 and a subset of our population with minimum long-term follow-up(LTF) of 5 years.

187 We analyzed long-term follow-up (LTFU) of efficacy outcomes and adve

188 .95) of participants in group 4 selected for long-term follow-up maintained a two times or greater in

189 At long-term follow-up (mean, 6.2 years +/- 2.5), treatment

190 On long-term follow-up (median 2.3 years) recurrent SCAD oc

191 During long-term follow-up (median of 2.7 years), the incidence

192 During long-term follow-up (median of 24 months), mortality was

193 Over long-term follow-up (median, 867 days), arrhythmia-free

194 From the time of surgery to long-term follow-up (median, 9.3 postoperative years), t

195 ogous, NCT00968760; allogeneic, NCT01497184; long-term follow-up, NCT01492036.

196 enty-two of 33 patients (67%) with available long-term follow-up neurocognitive testing had severe im

197 During the long-term follow-up, no serious adverse events occurred

198 Long term follow-up occurred for 173 uninfected and 106

199 Long term follow-up occurred for 173 uninfected and 106

200 At long-term follow-up, OCD symptoms decreased by 39% (p <

201 pancreatic duct ligation in minipigs and the long term follow up of the animal's health state.

202 We present a long term follow-up of a young female patient with choro

203 DESIGN, SETTING, AND PARTICIPANTS: Long-term follow-up of 2 placebo-controlled randomized c

204 We report efficacy and long-term follow-up of 21 patients with relapsed/refract

205 After a median long-term follow-up of 9 years (interquartile range, 3-1

206 This long-term follow-up of a randomized trial reporting no a

207 Few large prospective studies on long-term follow-up of adnexal masses exist.

208 Long-term follow-up of allergen-specific B cells in term

209 king from physical activity (PA) trials with long-term follow-up of both objectively measured PA leve

210 The utility of strain imaging in the long-term follow-up of CCS remains to be demonstrated.

211 esis studies in children with HBV infection; long-term follow-up of children on nucleoside or nucleot

212 Surgical success after long-term follow-up of children with PCG is low.

213 that longitudinal data are not available for long-term follow-up of individuals.

214 with increased risk of microcephaly based on long-term follow-up of infants and children who are HIV-

215 This is a report of the first long-term follow-up of infants from mothers receiving pr

216 During long-term follow-up of MADIT-CRT study patients with LBB

217 Long-term follow-up of participants treated before recur

218 We describe long-term follow-up of patients treated in RESONATE, whe

219 utility of anti-CD19 CAR T-cell therapy, but long-term follow-up of patients treated with anti-CD19 C

220 ealth-related quality of life are lacking in long-term follow-up of patients who remain cancer free a

221 Outcome data after extended long-term follow-up of patients with coronary artery dis

222 In a long-term follow-up of patients with NASH who underwent

223 Also, long-term follow-up of patients with TTP is crucial to i

224 Long-term follow-up of randomized nutritional trials is

225 Long-term follow-up of recipients on belatacept has demo

226 e best conditioning regimen, and the optimal long-term follow-up of such patients especially regardin

227 In a long-term follow-up of the CoBalT trial, we examined the

228 Long-term follow-up of the CvLPRIT trial shows that the

229 Conclusion With an 83% 8-year OS rate, long-term follow-up of the FOLL05 trial confirms the fav

230 Long-term follow-up of the treatment-related peripheral

231 initial presentation, mandating the need for long-term follow-up of these children.

232 Long-term follow-up of this cohort will allow further op

233 Further long-term follow-up of this special patient group is war

234 remained significantly increased, even after long-term follow-up of up to 20 years.

235 During long-term follow-up (of 5.6+/-6 years; range, 1 month to

236 The primary analysis is complete with long-term follow-up ongoing.

237 We analysed long-term follow-up outcomes of these patients.

238 beyond 5 years after diagnosis, we analysed long-term follow-up outcomes of this trial.

239 At long-term follow-up, patients with normal LAA function d

240 emic safety signals were observed during the long-term follow-up period.

241 Of these, 248 individuals completed a long-term follow-up questionnaire and provided data for

242 During long-term follow-up (range 15-48 months), VAS and utilit

243 ld setting, eyes that maintained consistent, long-term follow-up received significantly more intravit

244 Studies of large cohorts with long-term follow-up regarding recurrence are lacking.

245 Limitations of the study include no long-term follow-up, reliance on self-report rather than

246 timal management of mother and infant during long-term follow-up remains challenging, with very limit

247 To date there have been no long-term follow-up reports of what is for many a contro

248 Here, we report long-term follow-up results for the Costa Rica Vaccine T

249 Here, we report blinded long-term follow-up results for the IBIS-II trial, which

250 At long-term follow-up (results of which were available for

251 r raloxifene than tamoxifen in 1 trial after long-term follow-up (RR, 1.24 [95% CI, 1.05-1.47]; n = 1

252 Long-term follow-up shows that long periods of B cell ap

253 From baseline to long-term follow-up, significant declines were recorded

254 to environmental and social stressors, with long-term follow-up; social rather than biological endpo

255 Our findings suggest that, during long-term follow-up, strict BP control does not delay th

256 Real-world databases, biomarker and long-term follow up studies, and research involving spec

257 is the surgical standard for HD, controlled long-term follow-up studies evaluating bowel function an

258 is the surgical standard for HD, controlled long-term follow-up studies evaluating bowel function an

259 Long-term follow-up studies regarding disease-related co

260 Long-term follow-up studies will confirm the safety of L

261 Should our results be confirmed by long-term follow-up studies, POEM may become one of the

262 Long-term follow up study revealed three phenotypes of n

263 fetime Cohort Study (SJLIFE) and the St Jude Long-term Follow-up Study (SJLTFU).

264 This long-term follow-up study aimed to assess the prognosis

265 This is the first detailed long-term follow-up study for patients with XLA, reveali

266 Finally, a long-term follow-up study in 1 iTTP patient showed that

267 In this long-term follow-up study of 2 randomized trials, prior

268 In a long-term follow-up study of 2666 patients with chronic

269 In conclusion, in this long-term follow-up study of older adults, domestic work

270 This is a long-term follow-up study of the same cohort of patients

271 The patients could enter a long-term follow-up study until 1 year after allogeneic

272 We used data from the Gulf Long-term Follow-up Study, a cohort of workers and volun

273 In this long-term follow-up study, we collected our trial outcom

274 V vaccine group were invited to enrol in the long-term follow-up study, which extended follow-up for

275 We therefore performed a long-term follow-up study.

276 he last screening visit (year 11) exited the long-term follow-up study.

277 accinated control group were enrolled in the long-term follow-up study.

278 4,375 oil spill workers enrolled in the Gulf Long-Term Follow-up Study.

279 Long-term follow-up suggests that TG can be an effective

280 At long-term follow-up, survivors were an average of 13.8 y

281 In this community-based cohort with long-term follow-up, sustained hypertension in midlife t

282 and death, HF alone, and death alone during long-term follow-up than patients with discordant or les

283 With long-term follow-up, the benefits attributable to mesh a

284 In long-term follow-up, the prevalence of gallbladder polyp

285 In this large single-institution cohort with long-term follow-up, the risk of transformation was lowe

286 hort of patients with (18)F-FDG-avid TI with long-term follow-up to assess the validity of this appro

287 longitudinal cohort of 66 MS patients with a long-term follow-up (up to 20 years).

288 invite potential trial participants, and for long-term follow-up; use of prescreening to facilitate r

289 transplant exosomes in recipient blood over long-term follow-up using anti-HLA antibody, which was d

290 Median long-term follow-up was 3.1 years, and overall major adv

291 Median long-term follow-up was 5.4 years (IQR 4.9-5.7).

292 Long-term follow-up was complete in 1,380 patients (99%)

293 en October 31, 2012, and September 14, 2017; long-term follow-up was completed July 30, 2018.

294 Long-term follow-up was included in the third protocol a

295 Long-term follow-up will assess whether improved pCR in

296 Continued long-term follow-up will be important for the overall as

297 Class 1 presented during long-term follow-up with a low graft failure rate: 5% cl

298 Desensitized animals were sacrificed after long-term follow-up with functioning grafts.

299 sent clinical outcome data and toxicity in a long-term follow-up with individual absorbed dose estima

300 g EBV DNA-emia, including 7 who were lost to long-term follow-up, with a number of them developing hi